London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The fundraising will also enable the Company to progress its own work on COVID-19 and other viruses considerably more intensively. The Company had already been developing treatments to be deployed against other viral pathogens prior to the onset of COVID-19. The Company's ApbHC mice have been developed in part as a discovery platform for the development of such treatments. The Directors believe, for example, that the ApbHC could potentially be used as a tool for the rapid discovery and/or isolation of human antibodies against previously unknown viruses such as the novel coronavirus or other natural or engineered human-specific pathogens, referred to in biodefence circles as "Disease X".
The funds raised will also be used to advance IND-enabling studies for HEMO-CAR-T, the Company's product candidate which is being developed for the treatment of blood cancers such as AML (acute myeloid leukaemia), particularly with the aim of creating a "tuneable and controllable drug" which would greatly enhance the safety and versatility of HEMO-CAR-T cells in relation to blood cancers in an area where CAR-T based treatment has had some success but where current efficacy and safety is far from perfect.
The Directors believe that a number of developments, in particular those mentioned above, have shown excellent results to date and look forward to taking these forward effectively in the coming months.
Total Voting Rights
Following Admission, the issued share capital of the Company will comprise 433,636,255 ordinary shares of 1p each. No ordinary shares are held in Treasury. The total number of voting rights in the Company will therefore be 433,636,255 and this figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Hemogenyx Pharmaceuticals Share News (HEMO)
2
Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
-0.35 -4.96% 6.70 6.60 6.80 7.05 6.70 7.05 8,947,646 14:56:30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.1 0.0 - 27
Print
Alert
Hemogenyx Pharmaceuticals PLC Result of AGM and Completion of Placing
04/06/2020 3:15pm
UK Regulatory (RNS & others)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Intraday Stock Chart
Thursday 4 June 2020
Click Here for more Hemogenyx Pharmaceuticals Charts.
TIDMHEMO
RNS Number : 0151P
Hemogenyx Pharmaceuticals PLC
04 June 2020
Hemogenyx Pharmaceuticals plc
(the "Company")
Result of Annual General Meeting and Completion of Placing
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented at the end of this announcement.
Completion of Placing
Following the shareholders' vote at the AGM to authorise the Directors to allot shares for cash, the Conditional Placing announced on 12 May 2020 to raise GBP2,500,000 (before expenses) at 7p per share has now become unconditional. Accordingly, 35,714,286 new ordinary shares of 1p each (the "Placing Shares") will now be allotted. An application has been made for the Placing Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing ("Admission") and it is expected that Admission will become effective and that dealing in the Placing Shares will commence on or around 5 June 2020. The Placing Shares will rank pari passu with the existing ordinary shares of the Company.
Operational Update
As it has not been possible to open up the AGM to shareholder discussion in the normal way a brief update on operations and developments is provided below.
As announced on 2 June 2020, the Company has agreed a three-month extension of the collaboration with a leading global pharmaceutical company ( " GlobalCo " ) for the successful preclinical development of the Company's lead candidate bi-specific CDX antibody. This collaboration complements the Company's own development work that is currently being undertaken. The Directors are pleased to have agreed this extension which shows GlobalCo's continuing commitment to the project despite delays created by the COVID-19 pandemic crisis which has seen the industry as a whole focussing on treatments for COVID-19 while being hampered by laboratory shutdowns over recent months.
The fundraising will also enable the Company to progress its own work on COVID-19 and other viruses considerably mo